CytomX Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• CytomX Therapeutics Inc CTMX.OQ reported quarterly adjusted earnings of 23 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 1 cents. The mean expectation of seven analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -53 cents to -1 cents per share.

• Revenue rose 43.2% to $38.09 million from a year ago; analysts expected $19.42 million.

• CytomX Therapeutics Inc's reported EPS for the quarter was 23 cents​.

• The company reported quarterly net income of $18.88 million.

• CytomX Therapeutics Inc shares had fallen by 40.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for CytomX Therapeutics Inc is $3.68

This summary was machine generated from LSEG data March 7 at 01:31 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)